Cuộc họp công bố kết quả kinh doanh Quý 2/2026 của MaxCyte (MXCT): Tái khẳng định dự báo khi quan hệ hợp tác với Genentech mở rộng
Doanh thu Quý 2/2026 của MaxCyte giảm 15% xuống 7,3 triệu USD, trong khi chi phí giảm và định hướng kinh doanh năm 2026 được giữ nguyên. Genentech và DTx hỗ trợ đà tăng trưởng trong nửa cuối năm.
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.